Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 3/20 | 0.41 |
| ▸ | DRD3 | P35462 | 3/20 | 0.41 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.40 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.40 |
| ▸ | DRD4 | P21917 | 2/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17014495 | 0.93 | ALDH1A1 (0.48) | ALDH1A1CYP3A4MAPTADRA2ADRD2 | |
| SCHEMBL17014487 | 0.85 | ALDH1A1 (0.48) | ALDH1A1CYP3A4MAPTADRA2ADRD2 | |
| SCHEMBL17014471 | 0.85 | ALDH1A1 (0.45) | ALDH1A1CYP3A4MAPTADRA2ADRD2 | |
| SCHEMBL17014479 | 0.84 | DRD2 (0.49) | ALDH1A1CYP3A4MAPTADRA2ADRD2 | |
| SCHEMBL17014529 | 0.80 | ALDH1A1 (0.43) | ALDH1A1CYP3A4MAPTADRA2ADRD2 | |
| SCHEMBL17014327 | 0.79 | ADRA1A (0.41) | ALDH1A1ADRA2ADRD2DRD3 | |
| SCHEMBL8437292 | 0.78 | DRD2 (0.47) | CYP3A4DRD2DRD3SIGMAR1 | |
| SCHEMBL8257850 | 0.78 | KCNH2 (0.41) | ALDH1A1CYP3A4MAPTDRD2DRD3 | |
| SCHEMBL2497472 | 0.77 | SIGMAR1 (0.44) | ALDH1A1CYP3A4MAPTADRA2ADRD2 | |
| SCHEMBL12260114 | 0.76 | ALDH1A1 (0.51) | ALDH1A1CYP3A4MAPTADRA2ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2900656-B1 | SPIRO RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS | SUNSHINE LAKE PHARMA CO LTD (CN) | 2017-05-17 | — | — | EP | disclosed |
| US-20150232509-A1 | SPIRO RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-08-20 | — | — | US | disclosed |
| US-20150232509-A1 | SPIRO RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232509-A1 | SPIRO RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS | HAVCR2, SLC10A1, SORD | ALDH1A1 588/4885CYP3A4 59/4885MAPT 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.